Previous 10 | Next 10 |
Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 PR Newswire CAMBRIDGE, Mass. , Oct. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call a...
2023-08-03 12:51:01 ET Summary Blueprint Medicines reported Q2 earnings with revenue of $57.6M (+57.6% Y/Y) but a net loss of $132.8M. The company unveiled a "precision at scale" growth strategy, targeting a $1.5 billion market, while emphasizing financial discipline and innovatio...
2023-08-03 11:40:42 ET Summary On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint Medicines' revenue for the second quarter of 2023 was $57...
2023-08-02 14:56:50 ET More on Blueprint Medicines Blueprint Medicines Corporation 2023 Q2 - Results - Earnings Call Presentation Blueprint Medicines Corporation ( BPMC ) Q2 2023 Earnings Call Transcript Blueprint Is Well-Positioned To Capitalize On ISM Market (M...
2023-08-02 13:00:51 ET Shares of Blueprint Medicines (NASDAQ: BPMC) were down more than 12% as of 12:45 p.m. on Wednesday after the healthcare company announced second-quarter earnings. The stock is still up more than 27% so far this year. Blueprint focuses on precision medi...
2023-08-02 11:52:06 ET Blueprint Medicines Corporation (BPMC) Q2 2023 Earnings Conference Call August 2, 2023, 8:00 am ET Company Participants Jenna Cohen - VP, IR Kate Haviland - CEO Philina Lee - CCO Fouad Namouni - President, R&D Mike Landsittel - ...
2023-08-02 07:16:09 ET Blueprint Medicines press release ( NASDAQ: BPMC ): Q2 GAAP EPS of -$2.19. Revenue of $57.6M (+57.6% Y/Y). Cost of Sales: Cost of sales was $2.3 million for the second quarter of 2023, as compared to $4.9 million for the second quarter of 2022. ...
Blueprint Medicines Reports Second Quarter 2023 Results PR Newswire -- Achieved $39.9 million in AYVAKIT ® /AYVAKYT ® (avapritinib) net product revenues and $57.6 million in total revenues in the second quarter of 2023 -- -- AYVAKIT approved b...
2023-08-01 13:45:10 ET Blueprint Medicines ( NASDAQ: BPMC ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is -$2.49 (vs. -$2.68 last year) and the consensus Revenue Estimate is $45.6M (+24.9% Y/Y). ...
Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023 PR Newswire CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call a...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...